Sunshine Biopharma (SBFM) Gross Margin (2018 - 2026)

Sunshine Biopharma has reported Gross Margin for 9 years, with the latest figure at 26.96% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 371.0% year-over-year to 26.96%; the trailing twelve-month figure through Mar 2026 stood at 32.98% (up 250.0% YoY), and the FY2025 full-year result was 33.76%, up 316.0% from the prior year.
• Gross Margin for Q1 2026 stood at 26.96%, down from 35.31% in the prior quarter.
• The five-year high for Gross Margin was 51.2% in Q1 2022, with the low at 25.33% in Q2 2024.
• Historically, Gross Margin has averaged 36.11% across 5 years, with a median of 33.98% in 2024.
• Annual changes were most pronounced in 2023 — Gross Margin plunged 1706 bps — and 2025, when it soared 1105 bps.
• Sunshine Biopharma's Gross Margin stood at 37.85% in 2022, then declined by 12 bps to 33.44% in 2023, then declined by 4 bps to 32.24% in 2024, then climbed by 10 bps to 35.31% in 2025, then declined by 24 bps to 26.96% in 2026.
• The last three Gross Margin figures came in at 26.96% (Q1 2026), 35.31% (Q4 2025), and 32.64% (Q3 2025), per Business Quant data.